44 results on '"van Norden, Yvette"'
Search Results
2. Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment
- Author
-
Verduijn, Gerda M., Sijtsema, Nienke D., van Norden, Yvette, Heemsbergen, Wilma D., Mast, Hetty, Sewnaik, Aniel, Chin, Denzel, Baker, Sarah, Capala, Marta E., van der Lugt, Aad, van Meerten, Esther, Hoogeman, Mischa S., and Petit, Steven F.
- Published
- 2023
- Full Text
- View/download PDF
3. Development of a local dose-response relationship for osteoradionecrosis within the mandible
- Author
-
Sijtsema, Nienke D., Verduijn, Gerda M., Nasserinejad, Kazem, van Norden, Yvette, Mast, Hetty, van der Lugt, Aad, Hoogeman, Mischa S., and Petit, Steven F.
- Published
- 2023
- Full Text
- View/download PDF
4. Early and late contrast enhancing lesions after photon radiotherapy for IDH mutated grade 2 diffuse glioma
- Author
-
Jaspers, Jaap P.M., Taal, Walter, van Norden, Yvette, Zindler, Jaap D., Swaak, Annemarie T., Habraken, Steven J.M., Hoogeman, Mischa S., Nout, Remi, van den Bent, Martin J., and Méndèz Romero, Alejandra
- Published
- 2023
- Full Text
- View/download PDF
5. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling.
- Author
-
Hermans, Sjoerd J. F., van Norden, Yvette, Versluis, Jurjen, Rijneveld, Anita W., van der Holt, Bronno, de Weerdt, Okke, Biemond, Bart J., van de Loosdrecht, Arjan A., van der Wagen, Lotte E., Bellido, Mar, van Gelder, Michel, van der Velden, Walter J. F. M., Selleslag, Dominik, van Lammeren‐Venema, Daniëlle, van der Velden, Vincent H. J., de Wreede, Liesbeth C., Postmus, Douwe, Pignatti, Francesco, and Cornelissen, Jan J.
- Subjects
- *
LYMPHOBLASTIC leukemia , *ACUTE leukemia , *ADULTS - Abstract
Background: We recently reported results of the prospective, open‐label HOVON‐100 trial in 334 adult patients with acute lymphoblastic leukemia (ALL) randomized to first‐line treatment with or without clofarabine (CLO). No improvement of event‐free survival (EFS) was observed, while a higher proportion of patients receiving CLO obtained minimal residual disease (MRD) negativity. Aim: In order to investigate the effects of CLO in more depth, two multi‐state models were developed to identify why CLO did not show a long‐term survival benefit despite more MRD‐negativity. Methods: The first model evaluated the effect of CLO on going off‐protocol (not due to refractory disease/relapse, completion or death) as a proxy of severe treatment‐related toxicity, while the second model evaluated the effect of CLO on obtaining MRD negativity. The subsequent impact of these intermediate events on death or relapsed/refractory disease was assessed in both models. Results: Overall, patients receiving CLO went off‐protocol more frequently than control patients (35/168 [21%] vs. 18/166 [11%], p = 0.019; HR 2.00 [1.13–3.52], p = 0.02), especially during maintenance (13/44 [30%] vs. 6/56 [11%]; HR 2.85 [95%CI 1.08–7.50], p = 0.035). Going off‐protocol was, however, not associated with more relapse or death. Patients in the CLO arm showed a trend towards an increased rate of MRD‐negativity compared with control patients (HR MRD‐negativity: 1.35 [0.95–1.91], p = 0.10), which did not translate into a significant survival benefit. Conclusion: We conclude that the intermediate states, i.e., going off‐protocol and MRD‐negativity, were affected by adding CLO, but these transitions were not associated with subsequent survival estimates, suggesting relatively modest antileukemic activity in ALL. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Response to the letter-to-the-editor “Comments on: Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment”
- Author
-
Verduijn, Gerda M., Sijtsema, Nienke D., van Norden, Yvette, Heemsbergen, Wilma D., Mast, Hetty, Sewnaik, Aniel, Chin, Denzel, Baker, Sarah, Capala, Marta E., van der Lugt, Aad, van Meerten, Esther, Hoogeman, Mischa S., and Petit, Steven F.
- Published
- 2024
- Full Text
- View/download PDF
7. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML
- Author
-
Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, van Norden, Yvette, Biemond, Bart J., Schouten, Harry C., Spertini, Olivier, Vellenga, Edo, Graux, Carlos, Havelange, Violaine, de Greef, Georgine E., de Weerdt, Okke, Legdeur, Marie-Cecile J.C., Kuball, Juergen, Kooy, Marinus van Marwijk, Gjertsen, Bjorn T., Jongen-Lavrencic, Mojca, van de Loosdrecht, Arjan A., van Lammeren-Venema, Daniëlle, Hodossy, Beata, Breems, Dimitri A., Chalandon, Yves, Passweg, Jakob, Valk, Peter J.M., Manz, Markus G., and Ossenkoppele, Gert J.
- Published
- 2017
- Full Text
- View/download PDF
8. Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia
- Author
-
Libourel, Eduard J., Klerk, Clara P.W., van Norden, Yvette, de Maat, Moniek P.M., Kruip, Marieke J., Sonneveld, Pieter, Löwenberg, Bob, and Leebeek, Frank W.G.
- Published
- 2016
- Full Text
- View/download PDF
9. Prediction of Nonrelapse Mortality in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation with Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis
- Author
-
Hermans, Sjoerd J. F., Versluis, Jurjen, Labopin, Myriam, Giebel, Sebastian, van Norden, Yvette, Moiseev, Ivan, Blaise, Didier, Díez Martín, Jose L., Meijer, Ellen, Rovira, Montserrat, Choi, Goda, Raiola, Anna Maria, Koc, Yener, Reményi, P. ter, Vydra, Jan, Kröger, Nicolaus, Sica, Simona, Martino, Massimo, van Gorkom, Gwendolyn, Chevallier, Patrice, Busca, Alessandro, Herrera Arroyo, Concepcion, Brissot, Eolia, Peric, Zinaida, Nagler, Arnon, Shouval, Roni, Ciceri, Fabio, Cornelissen, Jan J., Mohty, Mohamad, Hematology, AII - Inflammatory diseases, CCA - Cancer Treatment and quality of life, CCA - Imaging and biomarkers, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, and MUMC+: MA Hematologie (9)
- Subjects
SCORING SYSTEMS ,Settore MED/15 - MALATTIE DEL SANGUE ,HIGH-RISK ,COMORBIDITY INDEX ,DIAGNOSIS TRIPOD ,Hematology ,NON-RELAPSE MORTALITY ,INDIVIDUAL PROGNOSIS ,CARDIAC TOXICITY ,BONE-MARROW-TRANSPLANTATION ,SINGLE-AGENT ,PREVENTION ,Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic - Abstract
Graft versus host disease (GVHD) prophylaxis with posttransplantation cyclophosphamide (PTCY) has been established to reduce severe GVHD, and thereby potentially reducing nonrelapse mortality (NRM) after allogeneic stem cell transplantation (alloSCT). We evaluated the predictive capacity of established NRM-risk scores in patients receiving PTCY-based GVHD prophylaxis, and subsequently developed and validated a novel PTCY-specific NRM-risk model. Adult patients (n = 1861) with AML or ALL in first complete remission who received alloSCT with PTCY-based GVHD prophylaxis were included. The PTCY-risk score was developed using multivariable Fine and Gray regression, selecting parameters from the hematopoietic cell transplantation-comorbidity index (HCT-CI) and European Group for Blood and Marrow Transplantation (EBMT) score with a subdistribution hazard ratio (SHR) of >= 1.2 for 2-year NRM in the training set (70% split), which was validated in the test set (30%). The performance of the EBMT score, HCT-CI, and integrated EBMT score was relatively poor for discriminating 2-year NRM (c-statistic 51.7%, 56.6%, and 59.2%, respectively). The PTCY-risk score included 10 variables which were collapsed in 3 risk groups estimating 2-year NRM of 11% +/- 2%, 19% +/- 2%, and 36% +/- 3% (training set, c-sta-tistic 64%), and 11% +/- 2%, 18% +/- 3%, and 31% +/- 5% (test set, c-statistic 63%), which also translated into different overall survival. Collectively, we developed an NRM-risk score for acute leukemia patients receiving PTCY that better predicted 2-year NRM compared with existing models, which might be applicable to the specific toxicities of high-dose cyclophosphamide.
- Published
- 2023
10. The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands
- Author
-
Dinmohamed, Avinash G., van Norden, Yvette, Visser, Otto, Posthuma, Eduardus F.M., Huijgens, Peter C., Sonneveld, Pieter, van de Loosdrecht, Arjan A., and Jongen-Lavrencic, Mojca
- Published
- 2015
- Full Text
- View/download PDF
11. A different perspective on conspicuity related motorcycle crashes
- Author
-
de Craen, Saskia, Doumen, Michelle J.A., and van Norden, Yvette
- Published
- 2014
- Full Text
- View/download PDF
12. Analysing the development of road safety using demographic data
- Author
-
Stipdonk, Henk, Bijleveld, Frits, van Norden, Yvette, and Commandeur, Jacques
- Published
- 2013
- Full Text
- View/download PDF
13. Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)
- Author
-
Ossenkoppele, Gert J., Stussi, Georg, Maertens, Johan, van Montfort, Kees, Biemond, Bart J., Breems, Dimitri, Ferrant, August, Graux, Carlos, de Greef, Georgine E., Halkes, C. J.M., Hoogendoorn, Mels, Hollestein, Rene M., Jongen-Lavrencic, Mojca, Levin, Mark D., van de Loosdrecht, Arjan A., van Marwijk Kooij, Marinus, van Norden, Yvette, Pabst, Thomas, Schouten, Harry C., Vellenga, Edo, Verhoef, Gregor E.G., de Weerdt, Okke, Wijermans, Pierre, Passweg, Jakob R., and Löwenberg, Bob
- Published
- 2012
- Full Text
- View/download PDF
14. Inter- and intrafraction dose variations in robotic stereotactic body radiation therapy (SBRT) for perihilar cholangiocarcinoma in the prospective phase I STRONG trial.
- Author
-
Paronetto, Chiara, den Toom, Wilhelm, Milder, Maaike T. W., van Norden, Yvette, Baak, Rogier, Heijmen, Ben J. M., and Méndez Romero, Alejandra
- Subjects
STEREOTACTIC radiotherapy ,CHOLANGIOCARCINOMA ,ROBOTICS - Abstract
Using fiducial-marker-based robotic respiratory tumor tracking, we treated perihilar cholangiocarcinoma patients in the STRONG trial with 15 daily fractions of 4 Gy. For each of the included patients, in-room diagnostic-quality repeat CTs (rCT) were acquired pre- and post-dose delivery in 6 treatment fractions to analyze inter- and intrafraction dose variations. Planning CTs (pCTs) and rCTs were acquired in expiration breath-hold. Analogous to treatment, spine and fiducials were used to register rCTs with pCTs. In each rCT, all OARs were contoured, and the target was rigidly copied from the pCT based on grey values. The rCTs acquired were used to calculate the doses to be delivered through the treatment-unit settings. On average, target doses in rCTs and pCTs were similar. However, due to target displacements relative to the fiducials in rCTs, 10% of the rCTs showed PTV coverage losses of >10%. Although target coverages had been planned below desired values in order to protect OARs, many pre-rCTs contained OAR constraint violations: 44.4% for the 6 major constraints. Most OAR dose differences between pre- and post-rCTs were not statistically significant. The dose deviations observed in repeat CTs represent opportunities for more advanced adaptive approaches to enhancing SBRT treatment quality. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Post radiation mucosal ulcer risk after a hypofractionated stereotactic boost and conventional fractionated radiotherapy for oropharyngeal carcinoma.
- Author
-
Verduijn, Gerda M., Petit, Steven F., Lauwers, Iris, van Norden, Yvette, Sijtsema, Nienke D., Sewnaik, Aniel, Mast, Hetty, Capala, Marta, Nout, Remi, Baker, Sarah, van Meerten, Esther, Hoogeman, Mischa S., van der Lugt, Aad, and Heemsbergen, Wilma D.
- Subjects
CANKER sores ,MULTIPLE regression analysis ,OROPHARYNGEAL cancer ,HEAD & neck cancer ,RETROSPECTIVE studies ,ACQUISITION of data ,RISK assessment ,CANCER patients ,COMPARATIVE studies ,MEDICAL records ,RADIATION doses ,DESCRIPTIVE statistics ,RADIOSURGERY ,RADIATION injuries ,ORAL mucosa ,PROGRESSION-free survival ,SQUAMOUS cell carcinoma ,LONGITUDINAL method ,PROPORTIONAL hazards models ,DISEASE risk factors - Abstract
Post radiation mucosal ulcers (PRMU) after treatment for oropharyngeal squamous cell carcinoma (OPSCC) can have a huge negative impact on patients' quality of life, but little is known concerning risk factors and the impact of fraction size. Therefore, the goal of this study was to determine the pattern of PRMU development and to identify risk factors after a hypofractionated stereotactic body radiotherapy boost (SBRT) compared to conventionally fractionated radiotherapy for OPSCC. We performed a retrospective cohort study (N = 332) of OPSCC patients with ≥ 1-year disease-free survival, treated with 46 Gy Intensity Modulated Radiotherapy (IMRT) (2 Gy fractions) followed by either an SBRT boost of 16.5 Gy (5.5 Gy fractions) (N = 180), or 24 Gy IMRT (2 Gy fractions) (N = 152). PRMU (grade ≥ 2) was scored when observed > three months after the last radiotherapy (RT) fraction (CTCAE v5.0). Potential risk factors were analyzed with Cox regression models using death as competing risk. Dose at the PRMU site was calculated by projecting delineated PRMU on the planning CT. All cases of PRMU (N = 64) occurred within 24 months; all were grade 2. The cumulative incidence at 2 years in the SBRT boost group was 26% (N = 46) vs. 12% (N = 18) for conventional fractionation (p = 0.003). Most PRMU developed within nine months (N = 48). PRMU occurring > nine months (N = 16) were mainly observed in the SBRT boost group (N = 15). Sex (p = 0.048), acute tube feeding (p = < 0.001), tumor subsite tonsil (p = 0.001), and N stage (p = 0.017) were associated with PRMU risk at multivariable regression in the hypofractionated SBRT boost group. All 25 delineated PRMU were located within the high dose regions. The risk of PRMU should be included in the cost benefit analysis when considering future research using a hypofractionated SBRT boost for OPSCC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. B and T cell imbalances in CSF of patients with Hu-antibody associated PNS
- Author
-
de Graaf, Marieke, de Beukelaar, Janet, Bergsma, Jelmer, Kraan, Jaco, van den Bent, Martin, Klimek, Markus, van Norden, Yvette, Kusuma, Arinardi, Smitt, Peter Sillevis, and Gratama, Jan Willem
- Published
- 2008
- Full Text
- View/download PDF
17. No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies
- Author
-
de Beukelaar, Janet W., Verjans, Georges M., van Norden, Yvette, Milikan, Johannes C., Kraan, Jaco, Hooijkaas, Herbert, Sintnicolaas, Kees, Gratama, Jan W., and Sillevis Smitt, Peter A.
- Published
- 2007
- Full Text
- View/download PDF
18. Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis
- Author
-
Schuurmans, Mascha, Bromberg, Jacoline E. C., Doorduijn, Jeanette, Poortmans, Philip, Taphoorn, Martin J. B., Seute, Tatjana, Enting, Roelien, Van Imhoff, Gustaaf, Van Norden, Yvette, and Van Den Bent, Martin J.
- Published
- 2010
- Full Text
- View/download PDF
19. Feasibility and efficacy of addition of individualized dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia
- Author
-
Kater, Arnon P, van Oers, Marinus H J, van Norden, Yvette, van der Straten, Lina, Driessen, Julia, Posthuma, Ward F M, Schipperus, Martinus, Chamuleau, Martine E D, Nijland, Marcel, Doorduijn, Jeanette K, Van Gelder, Michel, Hoogendoorn, Mels, De Croon, Francien, Wittebol, Shulamiet, Kerst, J Martijn, Marijt, Erik W A, Raymakers, Reinier A P, Schaafsma, Martijn R, Dobber, Johan A, Kersting, Sabina A, Levin, Mark-David, and HOVON CLL study group
- Subjects
Hematology - Abstract
Lenalidomide has been proven to be effective but with a distinct and difficult to manage toxicity profile in the context of chronic lymphocytic leukemia, potentially hampering combination treatment with this drug. We conducted a phase 1-2 study to evaluate the efficacy and safety of six cycles of chlorambucil (7 mg/m 2 daily), rituximab (375 mg/m 2 cycle 1 and 500 mg/m 2 cycles 2-6) and individually-dosed lenalidomide (escalated from 2.5 mg to 10 mg) (induction-I) in first-line treatment of patients with chronic lymphocytic leukemia unfit for treatment with fludarabine, cyclophosphamide and rituximab. This was followed by 6 months of 10 mg lenalidomide monotherapy (induction-II). Of 53 evaluable patients in phase 2 of the study, 47 (89%) completed induction-I and 36 (68%) completed induction-II. In an intention-to-treat analysis, the overall response rate was 83%. The median progression-free survival was 49 months, after a median follow-up time of 27 months. The 2-and 3-year progression-free survival rates were 58% and 54%, respectively. The corresponding rates for overall survival were 98% and 95%. No tumor lysis syndrome was observed, while tumor flair reaction occurred in five patients (9%, 1 grade 3). The most common hematologic toxicity was grade 3-4 neutropenia, which occurred in 73% of the patients. In conclusion, addition of lenalidomide to a chemotherapy backbone followed by a fixed duration of lenalidomide monotherapy resulted in high remission rates and progression-free survival rates, which seem comparable to those observed with novel drug combinations including novel CD20 monoclonal antibodies or kinase inhibitors. Although lenalidomide-specific toxicity remains a concern, an individualized dose-escalation schedule is feasible and results in an acceptable toxicity profile. EuraCT number: 2010-022294-34.
- Published
- 2019
20. P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB‐VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.
- Author
-
Kersting, Sabina, Levin, Mark‐David, Dubois, Julie, van Norden, Yvette, Dobber, Johan, Jauw, Yvonne, van der Kevie‐Kersemaekers, Anne‐Marie, Mellink, Clemens, Da Cunha‐Bang, Caspar, Van Desr Burg, Leonie, Te Raa, Doreen, de Boer, Fransien, Droogendijk, Jolanda, Idink, Cecile, De Heer, Koen, Nijziel, Marten, Tick, Lidwine, Ludwig, Inge, Silbermann, Mathijs, and Beeker, Aart
- Published
- 2023
- Full Text
- View/download PDF
21. P-64 Incidence and risk factors of osteoradionecrosis of the mandible after modern radiotherapy for oropharyngeal carcinoma
- Author
-
Verduijn, Gerda M., Sijtsema, Nienke D., van Norden, Yvette, Heemsbergen, Wilma D., Mast, Hetty, Sewnaik, Aniel, Hove, Ivo ten, Chin, Denzel, Baker, Sarah, van der Lugt, Aad, Hoogeman, Mischa S., and Petit, Steven
- Published
- 2021
- Full Text
- View/download PDF
22. Patterns of Care of Cancers and Radiotherapy in Ethiopia.
- Author
-
Rick, Tara, Habtamu, Biruk, Tigeneh, Wondemagegnhu, Abreha, Aynalem, van Norden, Yvette, Grover, Surbhi, Assefa, Mathewos, and Incrocci, Luca
- Subjects
CANCER radiotherapy ,HEAD & neck cancer ,PALLIATIVE treatment ,CERVICAL cancer - Abstract
PURPOSE: Radiotherapy (RT) is an essential component of cancer treatment. There is a lack of RT services in sub-Saharan Africa as well as limited knowledge regarding clinical practices. The purpose of this study was to identify and describe the patterns for RT treatment in Ethiopia. METHODS AND MATERIALS: We performed a retrospective analysis of 1,823 patients treated with cobalt RT at a large referral hospital in Addis Ababa, Ethiopia, from May 2015 through January 2018. Paper charts were reviewed for patient and treatment characteristics. Descriptive statistics were computed using SPSS (IBM, Armonk, NY). RESULTS: Among patients treated for cancer, 98% (n = 1,784) were adults, 78% (n = 1,426) were female, 5% (n = 85) were HIV positive, 30% (n = 555) were from Addis Ababa, and the median age was 48 years (interquartile range [IQR], 38-58 years). Cervical cancer was the most frequent cancer treated (47%, n = 851), followed by breast cancer (15%, n = 274) and head and neck cancer (10%, n = 184). Seventy-three percent of patients (n = 1,339) presented at a late stage, and 62% (n = 1,138) received palliative RT. The wait times were the shortest for patients receiving palliative treatment (median, 0 days; IQR, 0-15 days; n = 1,138), whereas wait times were longer for patients receiving curative treatment (median, 150 days; IQR, 60-210 days; n = 685). Three percent of patients (n = 56) had documented grade 3 or 4 acute toxicity; of these, 59% (n = 33) were patients with head and neck cancer. CONCLUSION: Cervical cancer accounted for half of patients treated; thus, a majority of patients were adult females. Most patients had advanced-stage cancer, and goals of care were palliative. Wait times were long for patients with curative-intent cancer as a result of low capacity for RT services. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
23. Including historical data in the analysis of clinical trials: Is it worth the effort?
- Author
-
van Rosmalen, Joost, Dejardin, David, van Norden, Yvette, Löwenberg, Bob, and Lesaffre, Emmanuel
- Subjects
CLINICAL trials ,BAYESIAN analysis ,META-analysis ,ACUTE myeloid leukemia ,RANDOMIZED controlled trials - Abstract
Data of previous trials with a similar setting are often available in the analysis of clinical trials. Several Bayesian methods have been proposed for including historical data as prior information in the analysis of the current trial, such as the (modified) power prior, the (robust) meta-analytic-predictive prior, the commensurate prior and methods proposed by Pocock and Murray et al. We compared these methods and illustrated their use in a practical setting, including an assessment of the comparability of the current and the historical data. The motivating data set consists of randomised controlled trials for acute myeloid leukaemia. A simulation study was used to compare the methods in terms of bias, precision, power and type I error rate. Methods that estimate parameters for the between-trial heterogeneity generally offer the best trade-off of power, precision and type I error, with the meta-analytic-predictive prior being the most promising method. The results show that it can be feasible to include historical data in the analysis of clinical trials, if an appropriate method is used to estimate the heterogeneity between trials, and the historical data satisfy criteria for comparability. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
24. P565: REAL-WORLD DATA AS SUPPLEMENTARY CONTROLS FOR THE PROSPECTIVE RANDOMIZED HOVON-103 TRIAL IN INTENSIVELY TREATED ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS.
- Author
-
Hermans, Sjoerd, van Norden, Yvette, van Werkhoven, Erik, Dinmohamed, Avinash, Huijgens, Peter, Ossenkoppele, Gert, Huls, Gerwin, Löwenberg, Bob, Pabst, Thomas, Breems, Dimitri, Postmus, Douwe, Pignatti, Francesco, Versluis, Jurjen, and Cornelissen, Jan
- Published
- 2023
- Full Text
- View/download PDF
25. Patterns of Primary Treatment, Trial Participation and Survival in Adult Acute Myeloid Leukemia: A Nationwide Population-Based Study Among Patients Diagnosed in the Netherlands from 1989 to 2012
- Author
-
Dinmohamed, Avinash G, Visser, Otto, van Norden, Yvette, Blijlevens, Nicole MA, Cornelissen, Jan J., Huls, Gerwin A, Huijgens, Peter C, Sonneveld, Pieter, van de Loosdrecht, Arjan A, Ossenkoppele, Gert J, Löwenberg, Bob, and Jongen-Lavrencic, Mojca
- Published
- 2014
- Full Text
- View/download PDF
26. Crash Involvement of Motor Vehicles in Relationship to the Number and Severity of Traffic Offenses. An Exploratory Analysis of Dutch Traffic Offenses and Crash Data.
- Author
-
Goldenbeld, Charles, Reurings, Martine, Van Norden, Yvette, and Stipdonk, Henk
- Subjects
TRAFFIC accidents ,TRAFFIC violations ,STATISTICS ,AUTOMOBILE speed ,LAW enforcement ,DATA analysis ,TRAFFIC safety - Abstract
Objective:To establish the statistical relationship between offenses and crashes when the unit of analysis is the vehicle instead of the driver, to show the influence of the severity (e.g., minor speed offenses) on this relationship, and to research whether the form of this relationship is similar in different enforcement contexts. Methods:An exploratory analysis was conducted using Dutch traffic offense and crash data. Crash data included all police-registered crashes involving motorized and registered vehicles in 2009; offense data included all non-criminal traffic offenses registered during 2005–2009 (mostly camera detected). Together these comprise an estimated 97 percent of all traffic offenses registered in this period. The analysis was done on a level of identified vehicles rather than persons. Vehicles involved in crashes were matched to vehicles involved in traffic offenses. The offense frequency distributions of registered crash involved vehicles and a random selection of vehicles was analyzed. Two comparisons were made: (1) privately owned vehicles versus company-owned vehicles and (2) vehicles for which only minor speed offenses were registered versus vehicles for which at least one major speed offense was registered. Results:An increase in traffic offense frequency coincides with a stronger increase in relative crash involvement. This relationship was adequately described by a power function. The slightly more than linear increase in the crash risk for vehicles with only minor speed offenses suggests that minor speed offenses (<10 km/h over the limit) contributed slightly to crashes. This relationship was unlikely to be caused by increased distance traveled only. For vehicles with at least one or more major speed violation an approximately quadratic increase of crash risk with increasing speed offense frequency was found. A comparison of Dutch and Canadian data showed a much more progressive offense–crash relationship in the Dutch data. Conclusion:The crash involvement of vehicles increased more than linearly with the number of minor traffic violations. Thus, automatic detection of minor offenses bears relevance to safety. The substantial increase in crash rates with speed offense frequency for vehicles with at least one major speed violation suggests that these vehicles represent a specific group with a significantly increased crash risk, especially in the case of many minor offenses. The more progressive relationship between offenses and crashes in The Netherlands when compared to Canada was hypothesized to result from the higher intensity camera enforcement levels and less severe consequences in the Dutch enforcement and adjudication system. Supplemental materials are available for this article. Go to the publisher's online edition ofTraffic Injury Preventionto view the supplemental file. [ABSTRACT FROM PUBLISHER]
- Published
- 2013
- Full Text
- View/download PDF
27. No evidence for the presence of HuD-specific T cells in the cerebrospinal fluid of patients with Huassociated paraneoplastic neurological syndromes.
- Author
-
de Beukelaar, Janet W., Milikan, Johannes C., Verjans, Georges M., de Graaf, Marieke T., van Norden, Yvette, Lamers, Cor H., van den Bent, Martin J., Bromberg, Jacoline E., Hulsenboom, Esther, Sintnicolaas, Kees, Gratama, Jan W., and Smitt, Peter A. Sillevis
- Subjects
LETTERS to the editor ,CEREBROSPINAL fluid - Abstract
A letter to the editor is presented asserting that the cerebrospinal fluid of patients with Hu-associated paraneoplastic neurological syndromes does not contain HuD-specific T cells.
- Published
- 2009
- Full Text
- View/download PDF
28. No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies.
- Author
-
de Beukelaar, Janet W., Verjans, Georges M., van Norden, Yvette, Milikan, Johannes C., Kraan, Jaco, Hooijkaas, Herbert, Sintnicolaas, Kees, Gratama, Jan W., and Sillevis Smitt, Peter A.
- Subjects
PARANEOPLASTIC syndromes ,T cells ,ANTIGENS ,SMALL cell lung cancer ,BLOOD testing ,NEURONS ,SYNDROMES ,PATIENTS ,DISEASES - Abstract
In paraneoplastic neurological syndromes (PNS) associated with small cell lung cancer (SCLC) and Hu antibodies (Hu-PNS), Hu antigens expressed by the tumour hypothetically trigger an immune response that also reacts with Hu antigens in the nervous system, resulting in tumour suppression and neuronal damage. To gain more insight into the hypothesized CD8
+ T cell-mediated immune pathogenesis of these syndromes, we searched for circulating HuD-specific CD8+ T cells in a large cohort of Hu-PNS patients and controls. Blood was tested from 43 Hu-PNS patients, 31 Hu antibody negative SCLC patients without PNS and 54 healthy controls. Peripheral blood mononuclear cells (PBMC) were stimulated with HuD protein-spanning peptide pools (15-mers) and individual HuD-derived peptides (9-mers) and analysed by cytokine flow cytometry and interferon-γ ELISPOT-assays. Additionally, HuD-based Class I HLA multimers were used to visualize HuD-specific CD8+ T cells. No HuD-specific CD8+ T cells could be detected in the blood of Hu-PNS patients or controls. Our results do not support a role for HuD-specific CD8+ T cells in Hu-PNS. Further studies should focus on the detection of circulating HuD-specific CD4+ T cells and examine the antigen specificity of T cells in affected tissues. [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
29. Pairings and actions for dynamical quantum groups
- Author
-
Koelink, Erik and van Norden, Yvette
- Subjects
- *
QUANTUM field theory , *MATHEMATICAL physics , *QUANTUM groups , *HYPERGEOMETRIC series - Abstract
Abstract: Dynamical quantum groups constructed from a FRST-construction using a solution of the quantum dynamical Yang–Baxter equation are equipped with a natural pairing. The interplay of the pairing with *-structures, corepresentations and dynamical representations is studied, and natural left and right actions are introduced. Explicit details for the elliptic dynamical quantum group are given, and the pairing is calculated explicitly in terms of elliptic hypergeometric functions. Dynamical analogues of spherical and singular vectors for corepresentations are introduced. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
30. THE DYNAMICAL U(n) QUANTUM GROUP.
- Author
-
KOELINK, ERIK and VAN NORDEN, YVETTE
- Published
- 2006
- Full Text
- View/download PDF
31. Stereotactic Body Radiation Therapy after Chemotherapy for Unresectable Perihilar Cholangiocarcinoma: The STRONG Trial, a Phase I Safety and Feasibility Study.
- Author
-
Baak, Rogier, Willemssen, François E. J. A., van Norden, Yvette, Eskens, Ferry A. L. M., Milder, Maaike T. W., Heijmen, Ben J. M., Koerkamp, Bas Groot, Sprengers, Dave, van Driel, Lydi M. J. W., Klümpen, Heinz-Josef, den Toom, Wilhelm, Koedijk, Merel S., IJzermans, Jan N. M., and Méndez Romero, Alejandra
- Subjects
PILOT projects ,SURVIVAL ,DISEASE progression ,CLINICAL trials ,CHOLANGIOCARCINOMA ,CANCER chemotherapy ,TREATMENT effectiveness ,QUALITY of life ,RADIOTHERAPY ,LONGITUDINAL method ,DRUG toxicity - Abstract
Simple Summary: The role of radiotherapy in the treatment of perihilar cholangiocarcinoma has not yet been properly defined. In this prospective study, we therefore explored the addition to first-line chemotherapy of stereotactic body radiation therapy (SBRT) delivered in 15 fractions. Patients eligible for the study had been diagnosed with unresectable perihilar cholangiocarcinoma, and then had no progressive disease after completing treatment with 6–8 cycles of cisplatin-gemcitabine. Primary endpoints were feasibility and safety. Secondary endpoints were local control, progression-free survival, overall survival, and quality of life. As each patient completed the SBRT successfully and no dose-limiting toxicity was found, we consider this treatment to be both feasible and safe. The local control rate and overall survival were promising. However, due to the small sample size of this study, we urge the analysis of this treatment in a larger series of patients. Background: In unresectable pCCA, the standard of care is palliative chemotherapy. We investigated the feasibility and safety of adding stereotactic body radiation therapy (SBRT) after chemotherapy. Methods: Patients with unresectable pCCA, stage T1-T4N0-N1M0, ECOG 0-1, having finished 6–8 cycles of cisplatin and gemcitabine without disease progression were eligible. SBRT was planned in 15 fractions of 3.0–4.5 Gy. The primary endpoints were feasibility (defined as completing SBRT as planned) and toxicity, evaluated within 3 months after SBRT (CTCAE v4.03). A conventional "3 + 3" design was used, corresponding to a sample size of 6 patients. Dose-limiting toxicity (DLT) was defined as grade ≥ 4 hepatobiliary or grade ≥ 3 gastrointestinal toxicity. The secondary endpoints, measured from the start of radiotherapy, were local control, progression-free survival, overall survival, and quality of life (QoL). ClinicalTrials.gov identifier: NCT03307538. Results: Six patients were enrolled between November 2017 and March 2020. SBRT was delivered as planned. All patients were treated with 60Gy (15 × 4.0Gy). No SBRT-related DLT was observed. The most common grade ≥ 3 toxicity was cholangitis (n = 5). The median follow-up was 14 months. The 12-month local control rate was 80%. We observed no substantial changes in QoL. Conclusion: In patients with unresectable pCCA with stable disease after palliative chemotherapy, adding SBRT is feasible and safe. The observed local control merits an additional evaluation of effectiveness. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. Treatment of Primary CNS Lymphoma in the Elderly, a Multicenter Retrospective Analysis
- Author
-
Bromberg, Jacoline E.C., Doorduyn, Jeanette, Schuurmans, Macha, Poortmans, Philip, Taphoorn, Martin J.B., Seute, Tatjana, Dekker, Adriaan W., Enting, Roelien H., van Imhoff, Gustaaf, van Norden, Yvette, and van den Bent, Martin
- Published
- 2008
- Full Text
- View/download PDF
33. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: A population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010.
- Author
-
Dinmohamed, Avinash G., Visser, Otto, van Norden, Yvette, Huijgens, Peter C., Sonneveld, Pieter, van de Loosdrecht, Arjan A., and Jongen-Lavrencic, Mojca
- Subjects
- *
MYELODYSPLASTIC syndromes treatment , *AGE distribution , *REPORTING of diseases , *MYELODYSPLASTIC syndromes , *SURVIVAL , *DISEASE incidence - Abstract
Abstract: Background: Studies with long-term follow-up of patients with myelodysplastic syndromes (MDS) based on data from nationwide population-based cancer registries are lacking. We conducted a nationwide population-based study to assess trends in incidence, initial treatment and survival in MDS patients diagnosed in the Netherlands from 2001 to 2010. Methods: We identified 5144 MDS patients (median age, 74years) from the Netherlands Cancer Registry (NCR). The NCR only includes MDS cases that were confirmed by bone marrow examinations. Information regarding initial treatment decisions was available in the NCR. Results: The age-standardised incidence rate of MDS was 2.3/100,000 in 2001–2005 and 2.8/100,000 in 2006–2010. The incidence increased with older age, with the highest incidence among those aged ⩾80years (32.1/100,000 in 2006–2010). Forty-nine percent of all MDS cases were unspecified. Of all patients, 89% receive no treatment or only supportive care and 8% were started on intensive therapy as initial treatment. Survival did not improve over time. The 5-year relative survival was 53%, 58%, 48%, 38% and 18% in patients with refractory anaemia (RA), RA with ringed sideroblasts, 5q-syndrome, refractory cytopenia with multilineage dysplasia, and RA with excess blasts, respectively. Conclusion: The incidence of MDS increased over time due to improved notification and better disease awareness, and has stabilised since 2007. The classification of MDS seems challenging as almost half of the pathologically confirmed cases were unspecified. The lack of improvement in survival might be explained by the limited availability of therapeutic agents. Therefore, ameliorated management and new treatment options are warranted. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
34. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA.
- Author
-
Schlenk, Richard F., Taskesen, Erdogan, Van Norden, Yvette, Krauter, Jürgen, Ganser, Arnold, Bullinger, Lars, Gaidzik, Verena I., Paschka, Peter, Corbacioglu, Andrea, Göhring, Gudrun, Kündgen, Andrea, Held, Gerhard, Götze, Katharina, Vellenga, Edo, Kuball, Juergen, Schanz, Urs, Passweg, Jakob, Pabst, Thomas, Maertens, Johan, and Ossenkoppele, Gert J.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *DRUG therapy , *ACUTE myeloid leukemia , *STEM cells , *THERAPEUTICS , *HEMATOLOGY - Abstract
The clinical value of allogeneic hematopoietic stem cell transplantation (alloHSCT) and autologous hematopoietic stem cell transplantation (autoHSCT) in the subtype of acute myeloid leukemia (AML) with double mutant CEBPA (CEBPAdm) has remained unsettled. Among 2983 patients analyzed for CEBPA mutational status (age 18-60 years) treated on 4 published Dutch-Belgian-Swiss Hemato-Oncology Cooperative Group (HOVON/SAKK) and 3 German-Austrian AML Study Group (AMLSG) protocols (2 published, 1 registered, clinicaltrials.gov NCT00151255), 124 had AIVIL with CEBPAdm and achieved first complete remission (CR1). Evaluation of the clinical impact of alloHSCT and autoHSCT vs chemotherapy was performed by addressing time dependency in the statistical analyses. Thirty-two patients proceeded to alloHSCT from a matched related (MRD, n = 29) or a matched unrelated donor (MUD, n = 3), 20 to autoHSCT in CR1 and 72 received chemotherapy. Relapse-free survival was significantly superior in.patients receiving an alloHSCT or autoHSCT in CR1 as compared with chemotherapy (P < .001), whereas overall survival was not different (P< .12). Forty-five patients relapsed. Of 42 patients treated with reinduction therapy, 35 achieved a second CR (83%) and most patients (n = 33) received an alloHSCT MRD, n = 11; MUD, n = 19; haplo-identical donor, n = 3). Survival of relapsed patients measured from date of relapse was 46% after 3 years. Adult AML patients with CEBPAdm benefit from alloHSCT and autoHSCT; relapsed patients still have a favorable outcome after reinduction followed by alloHSCT. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
35. Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling.
- Author
-
Taskesen, Erdogan, Havermans, Marije, van Lom, Kirsten, Sanders, Mathijs A., van Norden, Yvette, Bindels, Eric, Hoogenboezem, Remco, Reinders, Marcel J. T., Figueroa, Maria E., Valk, Peter J. M., Löwenberg, Bob, Meinick, Ari, and Delwel, Ruud
- Subjects
- *
MYELODYSPLASTIC syndromes , *ACUTE myeloid leukemia , *ANTISENSE DNA , *MESSENGER RNA , *DNA methylation , *CYTOLOGY - Abstract
Mutations in splice factor (SF) genes occur more frequently in myelodysplastic syndromes (MDS) than in acute myeloid leukemias (AML). We sequenced complementary DNA from bone marrow of 47 refractory anemia with excess blasts (RAEB) patients, 29 AML cases with low marrow blast cell count, and 325 other AML patients and determined the presence of SF-hotspot mutations in SF3B1, U2AF35, and SRSF2. SF mutations were found in 10 RAEB, 12 AML cases with low marrow blast cell count, and 25 other AML cases. Our study provides evidence that SF-mutant RAEB and SF-mutant AML are clinically, cytologically, and molecularly highly similar. An integrated analysis of genomewide messenger RNA (mRNA) expression profiling and DNA-methylation profiling data revealed 2 unique patient clusters highly enriched for SF-mutant RAEB/AML. The combined genomewide mRNA expression profiling/DNA-methylation profiling signatures revealed 1 SF-mutant patient cluster with an erythroid signature. The other SF-mutant patient cluster was enriched for NRAS/KRAS mutations and showed an inferior survival. We conclude that SF-mutant RAEB/AML constitutes a related disorder overriding the artificial separation between AML and MOS, and that SF-mutant RAEB/AML is composed of 2 molecularly and clinically distinct subgroups. We conclude that SF-mutant disorders should be considered as myeloid malignancies that transcend the boundaries of AML and MDS. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
36. Radiotherapy and Hyperthermia for Treatment of Primary Locally Advanced Cervix Cancer: Results in 378 Patients
- Author
-
Franckena, Martine, Lutgens, Ludy C., Koper, Peter C., Kleynen, Catharina E., van der Steen-Banasik, Elsbieta M., Jobsen, Jan J., Leer, Jan Willem, Creutzberg, Carien L., Dielwart, Michel F., van Norden, Yvette, Canters, Richard A.M., van Rhoon, Gerard C., and van der Zee, Jacoba
- Subjects
- *
CERVICAL cancer treatment , *CANCER patients , *CANCER radiotherapy , *CANCER thermotherapy , *PELVIC bones , *BONE tumors - Abstract
Purpose: To report response rate, pelvic tumor control, survival, and late toxicity after treatment with combined radiotherapy and hyperthermia (RHT) for patients with locally advanced cervical carcinoma (LACC) and compare the results with other published series. Methods and Materials: From 1996 to 2005, a total of 378 patients with LACC (International Federation of Gynecology and Obstetrics Stage IB2–IVA) were treated with RHT. External beam radiotherapy (RT) was applied to 46–50.4 Gy and combined with brachytherapy. The hyperthermia (HT) was prescribed once weekly. Primary end points were complete response (CR) and local control. Secondary end points were overall survival, disease-specific survival, and late toxicity. Patient, tumor, and treatment characteristics predictive for the end points were identified in univariate and multivariate analyses. Results: Overall, a CR was achieved in 77% of patients. At 5 years, local control, disease-specific survival, and incidence of late toxicity Common Terminology Criteria for Adverse Events Grade 3 or higher were 53%, 47%, and 12%, respectively. In multivariate analysis, number of HT treatments emerged as a predictor of outcome in addition to commonly identified prognostic factors. Conclusions: The CR, local control, and survival rates are similar to previously observed results of RHT in the randomized Dutch Deep Hyperthermia Trial. Reported treatment results for currently applied combined treatment modalities (i.e., RT with chemotherapy and/or HT) do not permit definite conclusions about which combination is superior. The present results confirm previously shown beneficial effects from adding HT to RT and justify the application of RHT as first-line treatment in patients with LACC as an alternative to chemoradiation. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
37. Externally Controlled Studies Using Real-World Data in Patients With Hematological Cancers: A Systematic Review.
- Author
-
Hermans SJF, van der Maas NG, van Norden Y, Dinmohamed AG, Berkx E, Huijgens PC, Rivera DR, de Claro RA, Pignatti F, Versluis J, and Cornelissen JJ
- Abstract
Importance: The use of real-world data (RWD) external control arms in prospective studies is increasing. The advantages, including the immediate availability of a control population, must be balanced with the requirements of meeting evidentiary standards., Objective: To address the question of whether and to what extent the methods of RWD studies compare to standard methods used in randomized clinical trials., Evidence Review: A systematic search across 4 electronic databases and Google Scholar was conducted from January 1, 2000, to October 23, 2023. Studies were included in the systematic review if they compared an intervention arm in a clinical trial to an RWD control arm in patients with hematological cancers and if they were published between 2000 and 2023., Findings: Thirty-two prospective intervention studies incorporating external control data from RWD sources of patients with hematological cancers were identified. A total of 4306 patients from intervention arms and 10 594 from RWD control arms were included across all studies. Only 2 studies (6%) included prospectively collected RWD. The complete trial inclusion criteria were applied to the RWD cohort in 7 studies (22%). Four studies (13%) published the statistical analysis plan and prespecified use of RWD. A total of 23 studies (72%) applied matching algorithms for trial and RWD cohorts, including matching for demographic, disease, and/or therapy-related characteristics. The end point criteria were the same as the trial in 8 studies (25%). In contrast, 12 studies (38%) used different end points, and 12 (38%) did not provide an end point definition for the RWD. Twelve studies (38%) had a median follow-up difference of less than a year between arms. Eight studies (25%) reported toxic effect data for the trial arm, of which 5 studies reported toxic effect data for the RWD arm., Conclusions and Relevance: In this systematic review, limitations were observed in the application of clinical trial eligibility criteria to RWD, statistical rigor and application of matching methods, the definition of end points, follow-up, and reporting of adverse events, which may challenge the conclusions reported in studies using RWD.
- Published
- 2024
- Full Text
- View/download PDF
38. The COMPLETE trial: HolistiC early respOnse assessMent for oroPharyngeaL cancEr paTiEnts; Protocol for an observational study.
- Author
-
Verduijn GM, Capala ME, Sijtsema ND, Lauwers I, Hernandez Tamames JA, Heemsbergen WD, Sewnaik A, Hardillo JA, Mast H, van Norden Y, Jansen MPHM, van der Lugt A, van Gent DC, Hoogeman MS, Mostert B, and Petit SF
- Subjects
- Humans, Observational Studies as Topic, Papillomaviridae genetics, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell pathology, Circulating Tumor DNA, Head and Neck Neoplasms, Oropharyngeal Neoplasms pathology, Papillomavirus Infections complications
- Abstract
Introduction: The locoregional failure (LRF) rate in human papilloma virus (HPV)-negative oropharyngeal squamous cell carcinoma (OPSCC) remains disappointingly high and toxicity is substantial. Response prediction prior to or early during treatment would provide opportunities for personalised treatment. Currently, there are no accurate predictive models available for correct OPSCC patient selection. Apparently, the pivotal driving forces that determine how a OPSCC responds to treatment, have yet to be elucidated. Therefore, the holistiC early respOnse assessMent for oroPharyngeaL cancer paTiEnts study focuses on a holistic approach to gain insight in novel potential prognostic biomarkers, acquired before and early during treatment, to predict response to treatment in HPV-negative patients with OPSCC., Methods and Analysis: This single-centre prospective observational study investigates 60 HPV-negative patients with OPSCC scheduled for primary radiotherapy (RT) with cisplatin or cetuximab, according to current clinical practice. A holistic approach will be used that aims to map the macroscopic (with Intra Voxel Incoherent Motion Diffusion Kurtosis Imaging (IVIM-DKI); before, during, and 3 months after RT), microscopic (with biopsies of the primary tumour acquired before treatment and irradiated ex vivo to assess radiosensitivity), and molecular landscape (with circulating tumour DNA (ctDNA) analysed before, during and 3 months after treatment). The main end point is locoregional control (LRC) 2 years after treatment. The primary objective is to determine whether a relative change in the mean of the diffusion coefficient D (an IVIM-DKI parameter) in the primary tumour early during treatment, improves the performance of a predictive model consisting of tumour volume only, for 2 years LRC after treatment. The secondary objectives investigate the potential of other IVIM-DKI parameters, ex vivo sensitivity characteristics, ctDNA, and combinations thereof as potential novel prognostic markers., Ethics and Dissemination: The study was approved by the Medical Ethical Committee of Erasmus Medical Center. The main results of the trial will be presented in international meetings and medical journals., Trial Registration Number: NL8458., Competing Interests: Competing interests: The department of radiotherapy has research collaborations with Elekta AB, Stockholm, Sweden and with Accuray, Sunnyvale, California, USA and Varian, Palo Alto, California, USA., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
39. Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation.
- Author
-
Kalin B, van Norden Y, van Gelder M, Breems D, Maertens J, Jongen-Lavrencic M, Broers AEC, Braakman E, Grob T, Zeijlemaker W, Ossenkoppele GJ, Meijer E, and Cornelissen JJ
- Subjects
- Adolescent, Adult, Aged, Decitabine therapeutic use, Humans, Lymphocytes, Middle Aged, Panobinostat, Transplantation, Homologous, Young Adult, Hematopoietic Stem Cell Transplantation
- Abstract
Outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is adversely affected by relapse to a considerable degree. To exploit the graft-versus-leukemia effect more effectively, we assessed the feasibility of early initiation of epigenetic therapy with panobinostat and decitabine after allo-HSCT and before donor lymphocyte infusion (DLI) in poor-risk patients with acute myeloid leukemia (AML) or refractory anemia with excess blasts with International Prognostic Scoring System score ≥1.5. A total of 140 poor-risk patients with AML aged 18 to 70 years were registered, and 110 proceeded to allo-HSCT. Three dose levels were evaluated for dose-limiting toxicities, including panobinostat monotherapy 20 mg at days 1, 4, 8, and 11 of a 4-week cycle (PNB mono group) and panobinostat combined with either decitabine 20 mg/m2 (PNB/DAC20 group) or decitabine 10 mg/m2 (PNB/DAC10 group) at days 1 to 3 of every 4-week cycle. After phase 1, the study continued as phase 2, focusing on completion of protocol treatment and treatment outcome. PNB mono and PNB/DAC10 were feasible, whereas PNB/DAC20 was not related to prolonged cytopenia. Sixty of 110 patients who underwent transplantation were eligible to receive their first DLI within 115 days after allo-HSCT. Grade 3 and 4 adverse events related to panobinostat and decitabine were observed in 23 (26%) of the 87 patients, and they received epigenetic therapy. Cumulative incidence of relapse was 35% (standard error [SE] 5), and overall survival and progression-free survival at 24 months were 50% (SE 5) and 49% (SE 5). Post-allo-HSCT epigenetic therapy with panobinostat alone or in combination with low-dose decitabine is feasible and is associated with a relatively low relapse rate. The trial was registered at the European Clinical Trial Registry, https://www.clinicaltrialsregister.eu, as ECT2012-003344-74., (© 2020 by The American Society of Hematology.)
- Published
- 2020
- Full Text
- View/download PDF
40. Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.
- Author
-
Kater AP, van Oers MHJ, van Norden Y, van der Straten L, Driessen J, Posthuma WFM, Schipperus M, Chamuleau MED, Nijland M, Doorduijn JK, Van Gelder M, Hoogendoorn M, De Croon F, Wittebol S, Kerst JM, Marijt EWA, Raymakers RAP, Schaafsma MR, Dobber JA, Kersting S, and Levin MD
- Subjects
- Adolescent, Adult, Chlorambucil administration & dosage, Disease-Free Survival, Feasibility Studies, Female, Humans, Lenalidomide administration & dosage, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Male, Middle Aged, Rituximab administration & dosage, Survival Rate, Vidarabine administration & dosage, Vidarabine analogs & derivatives, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell mortality
- Abstract
Lenalidomide has been proven to be effective but with a distinct and difficult to manage toxicity profile in the context of chronic lymphocytic leukemia, potentially hampering combination treatment with this drug. We conducted a phase 1-2 study to evaluate the efficacy and safety of six cycles of chlorambucil (7 mg/m
2 daily), rituximab (375 mg/m2 cycle 1 and 500 mg/m2 cycles 2-6) and individually-dosed lenalidomide (escalated from 2.5 mg to 10 mg) (induction-I) in first-line treatment of patients with chronic lymphocytic leukemia unfit for treatment with fludarabine, cyclophosphamide and rituximab. This was followed by 6 months of 10 mg lenalidomide monotherapy (induction-II). Of 53 evaluable patients in phase 2 of the study, 47 (89%) completed induction-I and 36 (68%) completed induction-II. In an intention-to-treat analysis, the overall response rate was 83%. The median progression-free survival was 49 months, after a median follow-up time of 27 months. The 2- and 3-year progression-free survival rates were 58% and 54%, respectively. The corresponding rates for overall survival were 98% and 95%. No tumor lysis syndrome was observed, while tumor flair reaction occurred in five patients (9%, 1 grade 3). The most common hematologic toxicity was grade 3-4 neutropenia, which occurred in 73% of the patients. In conclusion, addition of lenalidomide to a chemotherapy backbone followed by a fixed duration of lenalidomide monotherapy resulted in high remission rates and progression-free survival rates, which seem comparable to those observed with novel drug combinations including novel CD20 monoclonal antibodies or kinase inhibitors. Although lenalidomide-specific toxicity remains a concern, an individualized dose-escalation schedule is feasible and results in an acceptable toxicity profile. EuraCT number: 2010-022294-34 ., (Copyright© 2019 Ferrata Storti Foundation.)- Published
- 2019
- Full Text
- View/download PDF
41. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
- Author
-
Kater AP, Kersting S, van Norden Y, Dubois J, Dobber JA, Mellink CH, Evers LM, Croon-de Boer F, Schreurs J, van der Spek E, Visser H, Idink C, Wittebol S, Hoogendoorn M, Tonino SH, Mobasher M, and Levin MD
- Subjects
- Aged, Antibodies, Monoclonal, Humanized adverse effects, Antineoplastic Agents adverse effects, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Male, Middle Aged, Neoplasm, Residual, Remission Induction, Risk Factors, Tumor Lysis Syndrome etiology, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents therapeutic use, Bridged Bicyclo Compounds, Heterocyclic therapeutic use, Sulfonamides therapeutic use
- Abstract
Early data on venetoclax-containing regimens for the treatment of chronic lymphocytic leukemia (CLL) show promising results with deep remissions, but are hampered by potential risk for tumor lysis syndrome (TLS). Whether optimal duration of venetoclax treatment can be guided by minimal residual disease (MRD) is currently unknown. To study whether TLS risk can be mitigated in an unfit population by introducing preinduction, and whether MRD-guided duration of venetoclax treatment is a feasible and efficacious approach, we performed the Dutch-Belgian Cooperative Trial Group for Hemato-oncology (HOVON) 139/GIVE trial. The study treatment consists of 4 treatment phases: preinduction (2 cycles obinutuzumab), induction I (6 cycles obinutuzumab and venetoclax), induction II (6 cycles venetoclax), and a randomization phase (group A: maintenance with 12 additional cycles of venetoclax irrespective of MRD; group B: MRD guided venetoclax maintenance with a maximum of 12 cycles). Here we report on a planned interim safety analysis as well as preliminary efficacy and MRD data of the first 30 patients enrolled. Downgrading of TLS risk after preinduction occurred in 25 patients: 3 from high to medium, 3 from high to low, and 19 from medium to low risk. No patient remained high risk. From these 30 patients, peripheral blood MRD data were obtained for 28 patients at the end of induction II (6 months after the last obinutuzumab dose), of whom 26 had undetectable MRD levels, and for 18 patients who reached the 3-month after-randomization point, of whom 16 had undetectable MRD levels. Obinutuzumab preinduction is tolerated well in these unfit patients and results in abrogating high TLS risk in all patients. Preliminary data indicate that efficacy is maintained with a high proportion of patients with undetectable MRD levels after combination treatment., (© 2018 by The American Society of Hematology.)
- Published
- 2018
- Full Text
- View/download PDF
42. Hyperthermia dose-effect relationship in 420 patients with cervical cancer treated with combined radiotherapy and hyperthermia.
- Author
-
Franckena M, Fatehi D, de Bruijne M, Canters RA, van Norden Y, Mens JW, van Rhoon GC, and van der Zee J
- Subjects
- Adult, Aged, Aged, 80 and over, Body Size, Brachytherapy, Combined Modality Therapy methods, Female, Follow-Up Studies, Humans, Hyperthermia, Induced adverse effects, Logistic Models, Middle Aged, Multivariate Analysis, Neoplasm Staging, Radiotherapy Dosage, Retrospective Studies, Survival Rate, Treatment Outcome, Uterine Cervical Neoplasms radiotherapy, Hyperthermia, Induced methods, Uterine Cervical Neoplasms therapy
- Abstract
Adding hyperthermia to standard radiotherapy (RT+HT) improves treatment outcome for patients with locally advanced cervical cancer (LACC). We investigated the effect of hyperthermia dose on treatment outcome for patients with LACC treated with RT+HT. We collected treatment and outcome data of 420 patients with LACC treated with hyperthermia at our institute from 1990 to 2005. Univariate and multivariate analyses were performed on response rate, local control, disease-specific survival and toxicity for these patients to search for a thermal dose response relationship. Besides commonly identified prognostic factors in LACC like tumour stage, performance status, radiotherapy dose and tumour size, thermal parameters involving both temperature and duration of heating emerged as significant predictors of the various end-points. The more commonly used CEM43T90 (cumulative equivalent minutes of T90 above 43 degrees C) was less influential than TRISE (based on the average T50 increase and the duration of heating, normalised to the scheduled duration of treatment). CEM43T90 and TRISE measured intraluminally correlate significantly and independently with tumour control and survival. These findings stimulate further technological development and improvement of deep hyperthermia, as they strongly suggest that it might be worthwhile to increase the thermal dose for LACC, either by treatment optimisation or by prolonging the treatment time. These results also confirm the beneficial effects from hyperthermia as demonstrated in our earlier randomised trial, and justify applying radiotherapy and hyperthermia as treatment of choice for patients with advanced cervical cancer.
- Published
- 2009
- Full Text
- View/download PDF
43. No evidence for the presence of HuD-specific T cells in the cerebrospinal fluid of patients with Hu-associated paraneoplastic neurological syndromes.
- Author
-
de Beukelaar JW, Milikan JC, Verjans GM, de Graaf MT, van Norden Y, Lamers CH, van den Bent MJ, Bromberg JE, Hulsenboom E, Sintnicolaas K, Gratama JW, and Sillevis Smitt PA
- Subjects
- Aged, Autoantibodies analysis, Autoantibodies cerebrospinal fluid, Biomarkers analysis, Biomarkers cerebrospinal fluid, ELAV Proteins analysis, ELAV-Like Protein 4, Female, Humans, Immunoassay methods, Immunoglobulin G analysis, Immunoglobulin G cerebrospinal fluid, Immunophenotyping, Male, Middle Aged, Paraneoplastic Syndromes, Nervous System physiopathology, Predictive Value of Tests, Reproducibility of Results, Cerebrospinal Fluid cytology, ELAV Proteins cerebrospinal fluid, Paraneoplastic Syndromes, Nervous System cerebrospinal fluid, Paraneoplastic Syndromes, Nervous System immunology, T-Lymphocytes immunology
- Published
- 2009
- Full Text
- View/download PDF
44. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
- Author
-
Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck CA, Valk PJ, Beverloo HB, Löwenberg B, and Delwel R
- Subjects
- Adult, Aged, Alternative Splicing genetics, Cohort Studies, Cytogenetic Analysis, DNA-Binding Proteins metabolism, Female, Gene Expression Regulation, Leukemic, Humans, In Situ Hybridization, Fluorescence, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute genetics, MDS1 and EVI1 Complex Locus Protein, Male, Middle Aged, Multivariate Analysis, Prognosis, Protein Isoforms genetics, Protein Isoforms metabolism, RNA, Messenger genetics, RNA, Messenger metabolism, Reproducibility of Results, Survival Analysis, Transcription Factors metabolism, Treatment Outcome, Chromosome Aberrations, Chromosomes, Human, Pair 3 genetics, DNA-Binding Proteins genetics, Leukemia, Myeloid, Acute pathology, Proto-Oncogenes genetics, Transcription Factors genetics
- Abstract
Inappropriate expression of EVI1 (ecotropic virus integration-1), in particular splice form EVI1-1D, through chromosome 3q26 lesions or other mechanisms has been implicated in the development of high-risk acute myeloid leukemia (AML). To validate the clinical relevance of EVI1-1D, as well as of the other EVI1 splice forms and the related MDS1/EVI1 (ME) gene, real-time quantitative polymerase chain reaction was performed in 534 untreated adults with de novo AML. EVI1-1D was highly expressed in 6% of cases (n = 32), whereas 7.8% were EVI1(+) (n = 41) when all splice variants were taken into account. High EVI1 predicted a distinctly worse event-free survival (HR = 1.9; P = .002) and disease-free survival (HR = 2.1, P = .006) following multivariate analysis. Importantly, we distinguished a subset of EVI1(+) cases that lacked expression of ME (EVI1(+)ME(-); n = 17) from cases that were ME(+) (EVI1(+)ME(+); n = 24). The atypical EVI1(+)ME(-) expression pattern exhibited cytogenetically detectable chromosomal 3q26 breakpoints in 8 cases. Fluorescence in situ hybridization revealed 7 more EVI1(+)ME(-) cases that carried cryptic 3q26 breakpoints, which were not found in the EVI1(+)ME(+) group. EVI1(+)ME(-) expression predicts an extremely poor prognosis distinguishable from the general EVI1(+) AML patients (overall survival [OS]: P < .001 and event-free survival [EFS]: P = .002). We argue that EVI1/ME quantitative expression analysis should be implemented in the molecular diagnostic procedures of AML.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.